Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

@article{Fuchs2007RandomizedCT,
  title={Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.},
  author={Charles S. Fuchs and John Marshall and Edith Mitchell and Rafal Wierzbicki and Vinod Ganju and Mark Jeffery and Joseph J. Schulz and Donald Richards and Raoudha Soufi-Mahjoubi and B Wang and Jos{\'e} Barrueco},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 30},
  pages={4779-86}
}
PURPOSE This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI). PATIENTS AND METHODS A total of 430 previously untreated metastatic colorectal cancer patients were randomly assigned to receive FOLFIRI (n = 144), mIFL… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 284 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as firstline therapy for advanced colorectal cancer

  • DW Rea, JWR Nortier, WW Ten Bokkel Huinink
  • Ann Oncol 16:1123-1132,
  • 2005

Similar Papers

Loading similar papers…